Downloads
Abstract
Title: Evaluating the efficacy of TA chemotherapy regimen in the first line treatment of stage IV breast cancer. Aims: To evaluate the efficacy and toxicity of TA chemotherapy regimen in treatment of slaye IV breast cancer. Subjects and method: This was uncontrolled clinical intervention research of 43 patients with stage IV breast cancer, performing in K hospital from July 2011 to June 2013. Results: There were 222 cycles in total and the average number of cycle was 5.23±1.34. Patients were treated at least 2 cycles and maximum of 6 cycles. Overall responso rato in this research was 53.5%, with complete response rate of 9.3% and partial response rate of 44.2%. Response rate was significantly associated with number of metastasis organs, and was not related to endocrine receptor and her 2 neu conditions. Toxicity as neutropenia and low neutrophils were common with incident-rate of 54.9% and 50.7%, however grade 1 and 2 of neutropenia accounted for high proportion. Grade 3 and 4 of neutropenia did not usually occur. Low hemoglobin and thrombocytopenia were less common. Conclusions: TA chemotherapy regimen is a effective and safe regimen in treatment of stage IV breast cancer.
References
Ferlay J et al. "Estimates of worldwide burden of cancer in 2008", GLOBOCAN 2008. Int J Cancer 2010, 127, pp. 2893-2917.
Nguyen Ba Duc, Nguyen Thi Hoai Nga (2007), "Epidemiology of cancer", Diagnosis and treatment of cancer, 9-19.
Chia SK, Speers CH, D'yachkova Y, et al. "The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer". Cancer 2007, 110, pp. 973.
Gennari A, Conte P, Rosso R, et al. "Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies". Cancer 2005, 104, pp.1742.
Dawood S, Broglio K, Buzdar AU, et al. "Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review". J ClinOncol 2010, 28, pp. 92.
Biganzoli L, Cufer T et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol. 2002 Jul 15, 20(14), pp. 3114-21.
Planchard D. Soria JC, Michiels S. et al. Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer 2004, 100, pp. 28.
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25, pp. 5287.
Ebeling FG, Stieber P, Untch M, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002, 86, pp. 1217.
| Published | 22-02-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 44 (2017) | |
| Section | Original article | |
| DOI | ||
| Keywords | hiệu quả, phác đồ hoá chất, TA efficacy, TA chemotherapy regimen |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital